Clinical trials: Covid19 Vaccine
Covid19, Vaccine
Immunogenicity of the ChAdox1 n CoV-19 Vaccine With 12-dose Vial
ChAd0x1 nCoV-19 (AZD 1222) is the main vaccine that is planned to roll-out in Thailand and involve vaccinating people especially in high-risk categories.
- Conditions
- Covid19, Vaccine, Immunogenicity
- Trial name
- NCT04961385
- Testing
- Immunogenicity after first dose of participants who received first dose of ChAdox-1 n COV-19 vaccine
- Where
- Thailand
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Bangkok Metropolitan Administration Medical College and Vajira Hospital
Covid19
Africa COVID-19 Vaccine Hesitancy
Vaccine hesitancy is defined by the WHO's Strategic Advisory Group of Experts on Immunization as a 'delay in acceptance or refusal of vaccination despite availability of vaccination services'.
- Trial name
- ACHES (NCT04912284)
- Where
- 5 sites in Burkina Faso, Guinea and 3 more
- Volunteers
- 4,977 people, healthy volunteers welcome
- Sponsor
- Bernhard Nocht Institute for Tropical Medicine
Rheumatic Disease, HIV Infections
COVID-19 CoronaVac in Patients With Autoimmune Rheumatic Diseases and HIV/AIDS
Patients with chronic rheumatic diseases (such as systemic lupus erythematosus [SLE], rheumatoid arthritis [RA], ankylosing spondylitis [AS], juvenile idiopathic arthritis [JIA], poly/dermatomyositis [PM/DM], systemic sclerosis…
- Conditions
- Rheumatic Disease, HIV Infections, AIDS, Safety Issues
- Trial name
- CoronavRheum (NCT04754698)
- Testing
- CoronaVac
- Where
- Brazil
- Volunteers
- 2,196 people, healthy volunteers welcome
- Sponsor
- University of Sao Paulo General Hospital
Covid19
An Effectiveness Study of the Sinovac's Adsorbed COVID-19 (Inactivated) Vaccine
This is a stepped-wedge cluster randomized trial to assess effectiveness of Sinovac's Adsorbed COVID-19 (Inactivated) vaccine. Residents in the urban area of a municipality are eligible to participate.
- Trial name
- ProjetoS (NCT04747821)
- Testing
- Adsorbed COVID-19 (Inactivated) Vaccine
- Where
- Brazil
- Volunteers
- 27,711 people, healthy volunteers welcome
- Sponsor
- Butantan Institute
COVID-19
Puerto Rico COVID-19 Vaccine Uptake Study
The purpose of this study is to recruit a total of 386 participants to evaluate the effectiveness of an educational program to increase the proportion of men and women aged 21 years and older who have received the COVID-19…
- Trial name
- PR-COVACUPS (NCT05468021)
- Testing
- Educational intervention
- Where
- 2 sites in Puerto Rico
- Volunteers
- 394 people, healthy volunteers welcome
- Sponsor
- University of Puerto Rico
Healthy, Chronic Stable Illness
COVID-19 Study to Assess Immunogenicity, Safety, and Tolerability of Moderna mRNA-1273 Vaccine Administered With Casirivimab+Imdevimab in Healthy Adult Volunteers
The primary objectives of the study are: To evaluate the extent of effect, if any, of REGN10933+REGN10987 administration on vaccine-induced neutralizing antibody responses to SARS-CoV-2 by Moderna mRNA-1273 To evaluate the time…
- Trial name
- NCT04852978
- Testing
- casirivimab+imdevimab, Moderna mRNA-1273 vaccine
- Where
- 6 sites in United States
- Volunteers
- 295 people, healthy volunteers welcome
- Sponsor
- Regeneron Pharmaceuticals
Covid19, Severe Acute Respiratory Syndrome
Safety and Tolerability of COVID-19 Vaccine (ABNCoV2)
This phase 1 trial aims to assess the safety and tolerability of two doses of ABNCoV2, formulated with and without the adjuvant MF59, in healthy adult volunteers and to identify the dosage and formulation that optimizes the…
- Conditions
- Covid19, Severe Acute Respiratory Syndrome, SARS-CoV-2 Infection
- Trial name
- COUGH-1 (NCT04839146)
- Testing
- ABNCoV2 Vaccine
- Where
- Netherlands
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Radboud University Medical Center
SARS-CoV2 Infection, Immunisation Reaction
Effect of Different SARS-CoV-2 Vaccine Schedules and Vaccination Intervals on Reactogenicity and Humoral Immunogenicity
Investigation of the reactogenicity and immunogenicity of homologous and heterologous vaccine combinations with regard to the formation of SARS-CoV-2 antispike antibodies in health care workers after basic immunization and boost…
- Conditions
- SARS-CoV2 Infection, Immunisation Reaction, Antibody Hypersensitivity, Tolerance
- Trial name
- NCT05076227
- Testing
- IM injection of vaccination (mRNA vaccination), IM injection of vaccination (vector based vaccination)
- Where
- Germany
- Volunteers
- 1,206 people, healthy volunteers welcome
- Sponsor
- Serge Thal
COVID-19, SARS CoV 2 Infection
Immunogenicity and Safety of ChulaCov19 BNA159 and ChulaCov19 BNA159.2 Vaccines as a Booster Dose in Adults
This clinical trial is designed to assess the safety, tolerability and immunogenicity of a single dose of ChulaCov19 BNA159 and ChulaCov19 BNA159.2 vaccines as a booster dose, given at least 3 months after receipt of a previous…
- Trial name
- NCT05605470
- Testing
- ChulaCov19 BNA159 vaccine (50 mcg), Pfizer/BNT vaccine (30 mcg), COMVIGEN (ChulaCov19 BNA159.2) vaccine (50 mcg)
- Where
- 5 sites in Australia
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Technovalia, Pty Ltd
Coronavirus
A Study of a Candidate COVID-19 Vaccine (COV003)
A Randomized, Controlled, Phase III Study to Determine the Safety, Efficacy, and Immunogenicity of the Non-Replicating ChAdOx1 nCoV-19 Vaccine.
- Trial name
- NCT04536051
- Testing
- ChAdOx1 nCoV-19 single dose + paracetamol, MenACWY single dose + paracetamol, ChAdOx1 nCoV-19 two dose + paracetamol
- Where
- 6 sites in Brazil
- Volunteers
- 10,300 people, healthy volunteers welcome
- Sponsor
- University of Oxford
SARS-CoV-2
Safety and Immunogenicity of Glycovax-002 Vaccine in Healthy Adults
Glycovax Pharma has developed a glycoconjugate vaccine candidate called Glycovax-002 to fight the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) at the origin of COVID-19.
- Trial name
- NCT05799651
- Testing
- Glycovax-002
- Where
- Australia
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Glycovax Pharma Inc.
COVID-19, SARS-CoV-2
A Phase III Clinical Study of a SARS-CoV-2 Messenger Ribonucleic Acid (mRNA) Vaccine Candidate Against COVID-19 in Population Aged 18 Years and Above
Approximately 28,000 subjects will be enrolled in this trial. Eligible subjects will be stratified by age (<60 years of age and ≥60 years of age, the proportion of elderly people ≥60 years old is planned to be ≥25%) and randomly…
- Trial name
- NCT04847102
- Testing
- SARS-CoV-2 mRNA Vaccine
- Where
- 12 sites in Indonesia, Mexico
- Volunteers
- 28,000 people, healthy volunteers welcome
- Sponsor
- Walvax Biotechnology Co., Ltd.
Covid19, SARS-CoV-2
A Phase 2b/3, Randomized, Observer-Blinded, Placebo-Controlled, Multicenter Clinical Study Evaluating the Efficacy and Safety of Investigational SARS-CoV-2 mRNA Vaccine CVnCoV in Adults 18 Years of Age and Older
The primary objective of the randomized observer-blinded phase 2b/3 part of this trial is to demonstrate the efficacy of a 2-dose schedule of CVnCoV in the prevention of first episodes of virologically-confirmed cases of COVID-19…
- Trial name
- NCT04652102
- Testing
- CVnCoV, Authorized/licensed vaccines for preventing COVID-19 (AV) as standard of care through their national vaccination program
- Where
- 46 sites in Argentina, Belgium and 8 more
- Volunteers
- 39,680 people, healthy volunteers welcome
- Sponsor
- CureVac
COVID-19 Respiratory Infection, SARS CoV 2 Infection
Pancoronavirus Vaccine Study in Healthy Adults
Coronaviruses (CoVs) have caused the severe acute respiratory syndrome (SARS) outbreak, the Middle East Respiratory Syndrome (MERS) outbreak, and now the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic.
- Conditions
- COVID-19 Respiratory Infection, SARS CoV 2 Infection, COVID-19 Vaccine
- Trial name
- NCT06950177
- Testing
- CoV-RBD-scNP-001 and 3M-052-AF
- Where
- United States
- Volunteers
- 4 people, healthy volunteers welcome
- Sponsor
- Duke University
COVID-19
Safety and Immunogenicity of Adjuvanted SARS-CoV-2 (SCB-2019) Vaccine in Adults With Chronic Immune-Mediated Diseases
The purpose of the study is to evaluate the safety and immunogenicity of the investigational CpG 1018/Alum-adjuvanted recombinant SARS-CoV-2 trimeric spike (S)-protein subunit vaccine (SCB-2019) in adult participants with stable…
- Trial name
- COVID-19 (NCT05012787)
- Testing
- CpG 1018/Alum-adjuvanted SCB-2019 vaccine, Havrix
- Where
- 4 sites in Ukraine
- Volunteers
- 1 people
- Sponsor
- Clover Biopharmaceuticals AUS Pty
COVID-19
Dendritic Cell Vaccine, AV-COVID-19, to Prevent COVID-19 Infection
This is an adaptive Phase I trial of a vaccine consisting of autologous dendritic cells previously loaded ex vivo with SARS-CoV-2 spike protein, with or without GM-CSF, to prevent COVID-19 in adults.
- Trial name
- NCT04690387
- Testing
- AV-COVID-19, GM-CSF
- Where
- Indonesia
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- Aivita Biomedical, Inc.
COVID-19
A Safety and Immune Response Study to Evaluate Varying Doses of an mRNA Vaccine Against Coronavirus Disease 2019 (COVID-19) in Healthy Adults
The purpose of this study is to evaluate the safety, reactogenicity and immune responses of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) mRNA-CR-04 vaccine construct when administered in healthy adults…
- Trial name
- NCT05972993
- Testing
- mRNA-CR-04 vaccine 10μg, mRNA-CR-04 vaccine 30μg, mRNA-CR-04 vaccine 100μg
- Where
- 4 sites in United States
- Volunteers
- 114 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
COVID-19
Phase 3 Adolescent Study for SARS-CoV-2 rS Variant Vaccines
This study is a large-scale investigation (Phase 3) into a new booster shot designed specifically for teenagers. The booster targets a particular variant of COVID-19, Omicron XBB.1.5.
- Trial name
- COVID-19 (NCT05973006)
- Testing
- NVX-CoV2601 co-formulated Omicron XBB.1.5 SARS-CoV-2 rS vaccine, Prototype/XBB.1.5 Bivalent Vaccine (5 µg)
- Where
- 20 sites in United States
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Novavax
COVID-19 Immunisation, Influenza Vaccine
Evaluation of a Multilevel Intervention on Adult COVID-19 and Influenza Vaccination Rate
The study will test two tactics to improve uptake of two vaccines in adults. The vaccines prevent COVID-19 and influenza. Both are common and harmful. Most adults do not get either vaccine.
- Trial name
- NCT06646406
- Testing
- Patient letter and clinician communication
- Where
- 2 sites in United States
- Volunteers
- 114,165 people, healthy volunteers welcome
- Sponsor
- Mayo Clinic
COVID-19
Heterologous Boost Immunization with Ad5-nCoV After Three-dose Priming with an Inactivated SARS-CoV-2 Vaccine
This is an open-label, randomized, parallel-controlled clinical trial to evaluate the safety and immunogenicity of heterologous prime-boost immunization with an aerosolized (Ad5-nCoV-IH) or intramuscular (Ad5-nCoV-IM) Ad5-nCoV…
- Trial name
- NCT05303584
- Testing
- Ad5-nCoV-IH, Ad5-nCoV-IM, CoronaVac
- Where
- China
- Volunteers
- 362 people, healthy volunteers welcome
- Sponsor
- Jiangsu Province Centers for Disease Control and Prevention
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.